Fidelity Investments
DMAC icon

Fidelity Investments’s DiaMedica Therapeutics DMAC Stock Holding History

Fidelity Investments’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Sell
8,903
-1,560
-15% -$9.59K ﹤0.01% 4210
2026
Q1 		$70.8K Buy
10,463
+8,659
+480% +$68.6K ﹤0.01% 3960
2025
Q4 		$14.4K Buy
1,804
+1,707
+1,760% +$12.8K ﹤0.01% 4612
2025
Q3 		$666 Buy
+97
New +$526 ﹤0.01% 5062

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments's DMAC Position: Q2 2026 in Review

Fidelity Investments reduced its DiaMedica Therapeutics (DMAC) stake by 15% in Q2 2026, selling an estimated $9.59K and leaving 8,903 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4210.

Fidelity Investments first reported a position in DMAC in Q3 2025 and has held it in 4 quarters since. The position peaked at $70.8K in Q1 2026. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Fidelity Investments held 8,903 shares of DiaMedica Therapeutics worth $62.7K as of Q2 2026.
  • Fidelity Investments sold 1,560 DiaMedica Therapeutics shares in Q2 2026, an estimated $9.59K.
  • DiaMedica Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4210 holding.
  • Fidelity Investments first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Fidelity Investments's DiaMedica Therapeutics position peaked at $70.8K in Q1 2026.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.